Brief Summary of Potential SARS-CoV-2 Prophylactic and Treatment Drugs in the Emergency Department
نام عام مواد
[Article]
نام نخستين پديدآور
Brown, Cortlyn; Noble, Jeanne; Coralic, Zlatan
یادداشتهای مربوط به خلاصه یا چکیده
متن يادداشت
As of March 30th, 2020 there were 161,807 total cases and 2,953 total deaths of SARS-CoV-2 in the United States, with the number of cases expected to rise. Other than supportive care, there are no SARS-CoV-2 specific treatments available for patients discharged from the emergency department (ED) or those admitted to the hospital. In addition, there are no vaccines available to protect our at-risk healthcare workers. The National Institutes of Health is conducting a Phase 1 clinical trial to evaluate for a potential vaccine and the recipients have started to receive the investigational vaccine.2 We present a brief overview of the potential prophylactic and treatment agents under investigation, some which could be initiated in the ED if proven effective.
مجموعه
تاريخ نشر
2020
عنوان
Western Journal of Emergency Medicine: Integrating Emergency Care with Population Health
شماره جلد
21/3
نام شخص به منزله سر شناسه - (مسئولیت معنوی درجه اول )